Best in Biotech 13 Feb 2024
Eight biotechs thriving in Seattle
In this article, let us take a look at some of the major biotech companies in Seattle that are contributing to the biotech industry at large.
T-cells
- Latest Posts
More News! 4 Dec 2023
FDA CAR-T cell therapy warning: Are T cells malignant?
Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […]
Podcast 8 Sep 2023
Beyond Biotech podcast 62 – cytokine-based drugs
As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like interleukin 2 (IL-2) […]
News and Trends 25 Jul 2023
Crescendo Biologics raises $32M and expands cancer trial
Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […]
News and Trends 20 Jul 2023
CatalYm shows importance of GDF-15 in tumor immunotherapy resistance
CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […]
News and Trends 7 Jul 2023
CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology
CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent covers technologies for […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 21 Jun 2023
FDA clears T-Cell receptor natural killer cell therapy for sarcoma
Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […]
News and Trends 15 Jun 2023
IOME Bio claims breakthrough in cancer research
IOME Bio, a French seed stage biotechnology company focused on overcoming tumor resistance to immune checkpoint inhibition, has published its foundational research by founders Arlene Sharpe and Dennis Kasper in Nature. The company said its work reveals unique insights into the critical importance of the RGMb/PD-L2 pathway in immunotherapy resistance and further strengthens the significance […]
News and Trends 1 Jun 2023
Sanofi drug reduces disease activity in relapsing MS
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]
News and Trends 16 May 2023
LabGenius looks to create molecules with huge increase in tumor killing ability
LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […]
News and Trends 12 May 2023
Achilles Therapeutics’ new platform identifies most potent T-cell antigens
Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […]
News and Trends 4 May 2023
Osteoporosis drug helps T cells fight aggressive breast cancer
Researchers in Germany have discovered a mechanism by which cancer cells escape the immune system – and how to reverse it. Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer, with limited treatment options and a high probability of recurrence. Tumor growth and relapse of TNBC are driven by breast […]
ADVERTISEMENT